IL6 and breast carcinoma: In a longitudinal study involving 144 patients with breast cancer aged 50 + , Gilmore et al. reported a correlation between elevated serum levels of interleukin (IL)-6 and soluble tumor necrosis factor-alpha (TNF-alpha) with increased frailty post-chemotherapy [65].